.
of the life claims declined, 0.85 per cent were due to mis-representation and 0.16 per cent due to the definition of terminal illness not being met. .
.
cambridge's bluebird bio licenses delivery tech to novartis, gsk.
"we are calling for the immediate implementation of a statutory duty of candour for the health trusts.".
.